253 related articles for article (PubMed ID: 30076955)
1. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.
Uehlinger DE; Schaedeli F; Kinzig M; Sörgel F; Frey FJ
Antimicrob Agents Chemother; 1996 Aug; 40(8):1903-9. PubMed ID: 8843301
[TBL] [Abstract][Full Text] [Related]
3. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
4. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Kinzig M; Landersdorfer CB; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2011 Jun; 55(6):2927-36. PubMed ID: 21402834
[TBL] [Abstract][Full Text] [Related]
5. Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.
Bulitta JB; Jiao Y; Landersdorfer CB; Sutaria DS; Tao X; Shin E; Höhl R; Holzgrabe U; Stephan U; Sörgel F
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31295857
[TBL] [Abstract][Full Text] [Related]
6. Quinolone pharmacokinetics and metabolism.
Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
10. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
12. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
Schrenzel J; Cerruti F; Herrmann M; Leemann T; Weidekamm E; Portmann R; Hirschel B; Lew DP
Antimicrob Agents Chemother; 1994 Jun; 38(6):1219-24. PubMed ID: 8092817
[TBL] [Abstract][Full Text] [Related]
14. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Kearns GL
Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fleroxacin determined by biological method.
Verbist L; Van Hecken A; De Schepper P
J Chemother; 1989 Jul; 1(4 Suppl):572-3. PubMed ID: 16312537
[No Abstract] [Full Text] [Related]
16. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of fleroxacin in horses.
Rebuelto M; Otero P; Albarellos G; Ambros L; Kreil V; Waxman S; Montoya L; Hallu R
J Vet Pharmacol Ther; 2000 Apr; 23(2):103-5. PubMed ID: 10849255
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
20. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.
Bulitta JB; Jiao Y; Drescher SK; Oliver A; Louie A; Moya B; Tao X; Wittau M; Tsuji BT; Zavascki AP; Shin BS; Drusano GL; Sörgel F; Landersdorfer CB
Clin Pharmacokinet; 2019 Feb; 58(2):143-156. PubMed ID: 29936678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
